NR3C2 and diabetic kidney disease: The FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease (FIDELIO‐DKD)4 and FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease (FIGARO‐DKD)5 phase III trials evaluated the effect of the novel mineralocorticoid receptor antagonist (MRA) finerenone.